Merck & Company Inc (MRK)vsRevance Therapeutics, Inc. (RVNC)
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
RVNC
Revance Therapeutics, Inc.
$3.65
0.00%
HEALTHCARE · Cap: $381.02M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 25808% more annual revenue ($66.57B vs $256.94M). MRK leads profitability with a 4.8% profit margin vs -71.8%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
RVNC
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Intrinsic value data unavailable for RVNC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -2097.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RVNC
The strongest argument for RVNC centers on Debt/Equity. Revenue growth of 10.7% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RVNC
The primary concerns for RVNC are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while RVNC is a turnaround play — different risk/reward profiles.
RVNC carries more volatility with a beta of 0.95 — expect wider price swings.
RVNC is growing revenue faster at 10.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Revance Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?